Under treatment with SCT‐1015, a novel AMPK activator, the HIF1α protein abundance was reduced through the increased HIF1α protein degradation (ERK/PHD‐dependent HIF1α hydroxylation) and the decline of the HIF1α protein synthesis (mTORC1 signaling), eliciting an anti‐Warburg effect and an anti‐HCC effect. The gene discussed is PRKAA2; the disease is hepatocellular carcinoma.